933469-86-4Relevant academic research and scientific papers
Phenylcyclobutyl triazoles as selective inhibitors of 11β-hydroxysteroid dehydrogenase type I
Zhu, Yuping,Olson, Steven H.,Graham, Donald,Patel, Gool,Hermanowski-Vosatka, Anne,Mundt, Steven,Shah, Kashmira,Springer, Marty,Thieringer, Rolf,Wright, Samuel,Xiao, Jianying,Zokian, Hratch,Dragovic, Jasminka,Balkovec, James M.
scheme or table, p. 3412 - 3416 (2009/04/06)
3-(Phenylcyclobutyl)-1,2,4-triazoles were identified as selective inhibitors of 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1). These were active both in vitro and in an in vivo mouse pharmacodynamic (PD) model. Fluorine substitution of the cyclobutan
PROCESS FOR SYNTHESIZING 1,2,4-TRIAZOLES
-
Page/Page column 10-11, (2010/11/26)
The present invention relates to a process for production of 1,2,4-triazoles. The process comprises the reaction of a disubstituted amide and a hydrazide in the presence of POCl3.
NOVEL CRYSTALLINE FORMS OF AN INHIBITOR OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1
-
Page/Page column 8; 11, (2008/06/13)
Novel crystalline salts of 3-[1-(4-chlorophenyl)-trans-3-fluorocyclobutyl]-4,5-dicyclopropyl-r-4H-1,2,4-triazole are potent inhibitors of 11β-hydroxysteroid dehydrogenase Type 1 and are useful for the treatment of conditions associated with Metabolic Syndrome as well as cognitive impairment. The invention also relates to pharmaceutical compositions containing these novel salts, processes to prepare these salts and their pharmaceutical compositions as well as uses thereof for the treatment of Type 2 diabetes, hyperglycemia, obesity, dyslipidemia, hypertension, and cognitive impairment.
